ASX Announcement

Medibio Limited – 19 April 2016

Medibio Acquires Key IP

Medibio Limited (ASX: MEB) ("Medibio" or the "Company") advises it has acquired from Heartlink Limited the Australian, New Zealand and Israeli patents it held under exclusive licence on the 'method for diagnosing psychiatric disorders'. The method covers the use of 24-hour heart rate data and circadian heart rate (CHR) technology for the diagnosis of psychiatric conditions and the determination of the effectiveness of treatment.

Medibio will issue 4 million new ordinary shares, which will be escrowed for 12 months, as the full consideration for the acquisition. The acquisition is in line with Medibio's intellectual property (IP) strategy of creating and protecting a dominant, defensible position in the use of CHR technology in the areas of stress and mental health. Medibio has now completed the acquisition of all patents covering the use of 24-hour heart rate data for the diagnosis of psychiatric conditions.

Medibio also filed two patent applications in the US in June 2015 enhancing and expanding its IP base. The first titled "Method and System for Monitoring Stress Conditions" covers the use of CHR technology to assess the level and impact of stress. The second titled "Method and System for assessing Mental State" extends the use of Medibio's CHR technology for the diagnosis of depression and other mental health disorders. This second application covers discoveries made over the past 18 months and will, if granted, complement and extend the existing patents covering mental health diagnosis. Medibio intends filing PCT applications for these two patents prior to June 30 2016 to extend its IP protection across the major patent jurisdictions.

Table 1 – Showing Medibio Patent Coverage

Country	Patent #	Status	Title
Australia	720226	Granted	Method for diagnosing psychiatric disorders
Israel	132186	Granted	Method for diagnosing psychiatric disorders
New Zealand	337833	Granted	Method for diagnosing psychiatric disorders by analysis of heart rate patterns
USA	6245021	Granted	Method for diagnosing psychiatric disorders
Canada	228553	Granted	Method for diagnosing psychiatric disorders
USA	pending	Application	Method and System for Monitoring Stress Conditions
USA	pending	Application	Method and System for assessing Mental State

For the purposes of ASX Listing Rule 3.10.3, Medibio advises that it will issue 4,000,000 fully paid ordinary shares (ranking equally with ordinary shares on issue) at a price of 30 cents per share to Heartlink Limited. The purpose of the issue is the full consideration for the acquisition of the patents under the agreement which replaces the prior agreement. No shareholder approval will be sought in relation to this issue.

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in a clinical diagnosis. Clinical studies are being undertaken by Johns Hopkins University School of Medicine and Ottawa University, among others, to validate the test. This will potentially enable Medibio's technology to be the first FDA approved, objective, evidence based approach to the diagnosis mental health disorders for the medical industry. The technology also provides an objective method for the assessment of stress and mental wellbeing which can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.

Further Information:	Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979	**Medibio Media Enquiries to:** Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231